Literature DB >> 9793866

The profiles of clinical deterioration in schizophrenia.

T H McGlashan1.   

Abstract

Deterioration has been a part of the description and process of schizophrenia since Kraepelin. The underlying nature of these neurodynamic deficit processes remains unknown, but their clinical manifestations demonstrate somewhat predictable patterns of expression and progression. Symptomatically, strong affects and positive psychotic symptoms in the early course become less conspicuous with time and are replaced by more thought disorder, disorganized behavior, negative symptoms and deficit cognitive states. Subtypes, when unstable, drift from paranoid to disorganized and undifferentiated and from non-deficit to deficit. Longitudinal data from the schizophrenia sample of the Chestnut Lodge follow-up study illustrate some of these patterns. While the data remain heterogeneous, it is likely these deficit processes begin some time before the first manifest signs and symptoms of illness in the prodromal phase and are time limited, diminishing in activity at or shortly after onset in the majority of cases. Currently these processes appear irreversible but anecdotal experience with treatment in the very early phases of schizophrenia suggests that brain plasticity may be retained and that efforts at preventing deterioration should become a focus of active scientific clinical research.

Entities:  

Mesh:

Year:  1998        PMID: 9793866     DOI: 10.1016/s0022-3956(97)00015-0

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  5 in total

1.  Is schizophrenia a neurodegenerative disease? Evidence from age-related decline of brain-derived neurotrophic factor in the brains of schizophrenia patients and matched nonpsychiatric controls.

Authors:  Jagadeesh Rao; Joshua Chiappelli; Peter Kochunov; William T Regenold; Stanley I Rapoport; L Elliot Hong
Journal:  Neurodegener Dis       Date:  2014-12-17       Impact factor: 2.977

2.  Psychosis as a disorder of reduced cathectic capacity: Freud's analysis of the Schreber case revisited.

Authors:  Thomas H McGlashan
Journal:  Schizophr Bull       Date:  2009-04-08       Impact factor: 9.306

3.  Molecular profiles of schizophrenia in the CNS at different stages of illness.

Authors:  Sujatha Narayan; Bin Tang; Steven R Head; Timothy J Gilmartin; J Gregor Sutcliffe; Brian Dean; Elizabeth A Thomas
Journal:  Brain Res       Date:  2008-08-16       Impact factor: 3.252

4.  The schizophrenia prodrome: promise for prevention.

Authors:  B Cornblatt
Journal:  Dialogues Clin Neurosci       Date:  2001-06       Impact factor: 5.986

5.  Indicators of deterioration in young adults with serious mental illness: a systematic review protocol.

Authors:  Lindsay H Dewa; Elizabeth Cecil; Lynne Eastwood; Ara Darzi; Paul Aylin
Journal:  Syst Rev       Date:  2018-08-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.